Guizhou Yibai Pharmaceutical Co Ltd

Guizhou Yibai Pharmaceutical Co Ltd has a debt-to-equity ratio of 0.34, indicating a relatively conservative capital structure. However, the company reported negative net income of CNY -329.6 million and operating income of CNY -304.0 million, suggesting financial distress. Free cash flow is negative at CNY -227.7 million, and capital expenditures amounted to CNY -34.99 million, indicating ongoing investment but insufficient cash generation to support it. Profitability metrics are weak, with a return on equity of -15.06% and a return on assets of -9.58%, both significantly below industry norms. The company's operating cash flow of CNY 256.7 million is the only positive liquidity metric, but it is not sufficient to offset the negative net income and free cash flow. The company's revenue is concentrated in a single geographic market, China, with no disclosed international operations. There is no segment breakdown provided in the available data, making it difficult to assess the contribution of different product lines or therapeutic areas to overall performance. The company's growth trajectory is uncertain, with no clear indication of revenue expansion in the current fiscal year. The negative net income and operating income suggest a challenging operating environment, and there is no evidence of a turnaround in the near term. Risk factors include liquidity concerns, as the company has negative net cash after subtracting total debt. The risk of dilution is currently low, but the company's financial position may necessitate additional financing in the future, which could lead to share dilution. Recent events include the reporting of a last actual EPS of 0.18 CNY, which is a positive figure but does not reflect the broader financial distress indicated by the negative net income and operating income.